{"id":17938,"date":"2019-08-01T13:37:46","date_gmt":"2019-08-01T11:37:46","guid":{"rendered":"http:\/\/irdd-summit.com\/?page_id=17938"},"modified":"2021-03-19T10:15:45","modified_gmt":"2021-03-19T10:15:45","slug":"aernout-van-haarst","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/","title":{"rendered":"Aernout van Haarst"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Aernout van Haarst, PhD<\/h2>\n<h4>Director, Scientific Affairs at Celerion<\/h4>\n\t<p>As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise to support drug development programs of Celerion\u2019s clients. He is a member of Celerion\u2019s respiratory and vaccine research teams and is the scientific liaison to various external experts in the fields of pulmonology and vaccine development.<\/p>\n<p>Dr. van Haarst has over 20 year of drug development experience at biotechnology companies as well as CROs. This experience includes designing drug development strategies as well as hands-on experience in the design and conduct of early clinical studies in a breadth of therapeutic areas, and all clinical operational management including regulatory authority meetings.<\/p>\n<p>Dr. van Haarst earned his doctorate in Pharmacology from the School of Medicine at Leiden University (Netherlands) and also qualified as Clinical Pharmacologist in Leiden. He holds a Master\u2019s Degree in Medical Biology, from the School of Medicine at Utrecht University (Netherlands).<\/p>\n\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.irdd-summit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile.jpg\" alt=\"Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile\" itemprop=\"image\" title=\"Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD_Profile-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tEarly Phase Clinical Trials for Inhaled Drugs &#8211; Challenges and Opportunities\n\t<\/h3>\n\t<ul>\n<li>Considerations for development of inhaled drugs<\/li>\n<li>Rationale for inclusion of patients in early clinical development<\/li>\n<li>Operational hurdles for (hybrid) Phase I studies involving patients<\/li>\n<\/ul>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.celerion.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.celerion.com\/<\/a><\/p>\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener noreferrer\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n\t<p><a href=\"https:\/\/www.linkedin.com\/in\/aernout-van-haarst-b2b56a\/\" target=\"_blank\" rel=\"noopener noreferrer\">Visit Profile<\/a><\/p>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Aernout van Haarst, PhD Director, Scientific Affairs at Celerion As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise to support drug development programs of Celerion\u2019s clients. He is a member of Celerion\u2019s respiratory and vaccine research teams and is the scientific liaison to various&#8230;<\/p>\n","protected":false},"author":1,"featured_media":23998,"parent":15585,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-17938","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Aernout van Haarst &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aernout van Haarst &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-19T10:15:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/\",\"name\":\"Aernout van Haarst &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg\",\"datePublished\":\"2019-08-01T11:37:46+00:00\",\"dateModified\":\"2021-03-19T10:15:45+00:00\",\"description\":\"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inhalation &#038; Respiratory Drug Delivery 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aernout van Haarst\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aernout van Haarst &#8226; BioTech Pharma Summit","description":"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/","og_locale":"en_US","og_type":"article","og_title":"Aernout van Haarst &#8226; BioTech Pharma Summit","og_description":"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-19T10:15:45+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/","name":"Aernout van Haarst &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg","datePublished":"2019-08-01T11:37:46+00:00","dateModified":"2021-03-19T10:15:45+00:00","description":"As Director, Scientific Affairs, Dr. Aernout van Haarst plays a key role in leveraging Celerion\u2019s scientific and drug development expertise","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2019\/12\/Aernout_van-Haarst_Celerion_BioTech_Pharma_Summit_IRDD.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/aernout-van-haarst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Inhalation &#038; Respiratory Drug Delivery 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/"},{"@type":"ListItem","position":3,"name":"Aernout van Haarst"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/17938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=17938"}],"version-history":[{"count":20,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/17938\/revisions"}],"predecessor-version":[{"id":33628,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/17938\/revisions\/33628"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/15585"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/23998"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=17938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}